Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

被引：18

作者：

Medioni, Jacques ^{[1
,7
]}

Banu, Eugeniu ^{[1
]}

Helley, Dominique ^{[2
,7
,8
]}

Scotte, Florian ^{[1
]}

Fournier, Laure ^{[3
]}

Mejean, Arnaud ^{[4
]}

Chedid, Antoine ^{[5
]}

Azizi, Michel ^{[6
,7
]}

Andrieu, Jean-Marie ^{[1
,7
]}

Oudard, Stephane ^{[1
,7
]}

机构：

[1] Hop Europeen Georges Pompidou, AP HP, Dept Oncol, F-75015 Paris, France

[2] Hop Europeen Georges Pompidou, AP HP, Dept Biol, F-75015 Paris, France

[3] Hop Europeen Georges Pompidou, AP HP, Dept Radiol, F-75015 Paris, France

[4] Hop Europeen Georges Pompidou, AP HP, Dept Urol, F-75015 Paris, France

[5] Hop Europeen Georges Pompidou, AP HP, Dept Vasc Med, F-75015 Paris, France

[6] Hop Europeen Georges Pompidou, AP HP, Clin Res Ctr, F-75015 Paris, France

[7] Paris Descartes Univ, Paris, France

[8] INSERM, U765, Paris, France

来源：

EUROPEAN UROLOGY | 2009年 / 56卷 / 01期

关键词：

Bevacizumab; Renal cell carcinoma; Salvage therapy; Sunitinib; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; CANCER; INHIBITOR; ANTIBODY; SU11248;

D O I：

10.1016/j.eururo.2009.01.001

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile. Crown Copyright (C) 2009 Published by Elsevier B.V. on behalf of European Association of Urology. All rights reserved.

引用

页码：207 / 211

页数：5

共 14 条

[1] Home blood-pressure monitoring in patients receiving sunitinib [J].

Azizi, Michel ;

Chedid, Antoine ;

Oudard, Stephane .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :95-97

[2]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[3] Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [J].

DePrimo, Samuel E. ;

Bello, Carlo L. ;

Smeraglia, John ;

Baum, Charles M. ;

Spinella, Dominic ;

Rini, Brian I. ;

Michaelson, M. Dror ;

Motzer, Robert J. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5

[4] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].

Faivre, S ;

Delbaldo, C ;

Vera, K ;

Robert, C ;

Lozahic, S ;

Lassau, N ;

Bello, C ;

Deprimo, S ;

Brega, A ;

Massimini, G ;

Armand, JP ;

Scigalla, P ;

Raymond, E .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35

[5]

Feldman DR, 2007, J CLIN ONCOL, V25

[6]

HELLEY D, 2007, J THROMB HAEMOST, V5, pPS429

[7] Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [J].

Motzer, RJ ;

Michaelson, MD ;

Redman, BG ;

Hudes, GR ;

Wilding, G ;

Figlin, RA ;

Ginsberg, MS ;

Kim, ST ;

Baum, CM ;

DePrimo, SE ;

Li, JZ ;

Bello, CL ;

Theuer, CP ;

George, DJ ;

Rini, BI .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :16-24

[8] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

[9] Sunitinib in patients with metastatic renal cell carcinoma [J].

Motzer, Robert J. ;

Rini, Brian I. ;

Bukowski, Ronald M. ;

Curti, Brendan D. ;

George, Daniel J. ;

Hudes, Gary R. ;

Redman, Bruce G. ;

Margolin, Kim A. ;

Merchan, Jaime R. ;

Wilding, George ;

Ginsberg, Michelle S. ;

Bacik, Jennifer ;

Kim, Sindy T. ;

Baum, Charles M. ;

Michaelson, M. Dror .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2516-2524

[10] Treatment options in renal cell carcinoma: past, present and future [J].

Oudard, S. ;

George, D. ;

Medioni, J. ;

Motzer, R. .

ANNALS OF ONCOLOGY, 2007, 18 :25-31

← 1 2 →